Tatsuyuki Arai

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the suspension of the Phase II trials of its narcolepsy drug candidate TAK-994 due to safety issues. Following the suspension of this promising pipeline, the company’s growth recovery prospects appear dismal, according to BofA Securities. The...